Abbott launches pivotal trial of Cephea mitral valve replacement device
Bitget2026/10/29 13:05- Abbott initiated the CROWN-MV pivotal trial to evaluate the safety and effectiveness of its investigational Cephea mitral valve replacement system.
- The study will enroll up to 585 patients in the U.S., Canada and Europe.
- Eligible patients have moderate-to-severe or severe mitral regurgitation or calcium-related valve dysfunction and cannot undergo surgery or transcatheter repair.
- Cephea delivers a replacement tissue valve through a catheter inserted into a leg vein, offering a minimally invasive approach.
- Researchers will present 30-day early feasibility outcomes for Cephea's third-generation delivery system at TCT 2026 on Nov. 1.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pyth October Report: ARR Jumps 18.9% as Data Expansion Accelerates
Elon Musk: SpaceX (SPCX.US) Q4 revenue is expected to increase by approximately 70% quarter-on-quarter, with government contract income share falling below 10%
Elon Musk stated on Friday that SpaceX (SPCX.US) will continue to reduce its dependence on U.S. government procurement contracts.
After the sharp decline in tech stocks, the White House suddenly canceled the top tech advisor meeting the following day.
The White House has canceled the previously scheduled President’s Council of Advisors on Science and Technology meeting, which was set for Friday and includes prominent tech leaders such as Nvidia CEO Jensen Huang and Meta CEO Mark Zuckerberg. The Department of Energy's meeting page briefly listed November 13 as the new meeting date, but the agency later sent an email retracting this information. Currently, the specific date for rescheduling the meeting remains unclear.
Crypto prices
More
